Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phanes Therapeutics has selected Crown Bioscience (CrownBio) as a strategic partner to advance its oncology drug discovery pipeline.
Subscribe to our email newsletter
CrownBio provides the world’s largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments.
Phanes will gain access to CrownBio’s clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.
Phanes Therapeutics president and CEO Ming Wang, expressed enthusiasm about this partnership, saying: “We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules.
“We are very glad to partner with CrownBio. They have very unique MuPrime models, as well as Humanized GEMMs (HuGEMM) and Patient-Derived Xenograft (PDX) models for our oncology programs. We look forward to a productive partnership.”
CrownBio chief business officer Laurie Heilmann said: “We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds.
“Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer.”